JP7419268B2 - 変異kras配列及び脂質を含む化合物並びにその使用 - Google Patents

変異kras配列及び脂質を含む化合物並びにその使用 Download PDF

Info

Publication number
JP7419268B2
JP7419268B2 JP2020568946A JP2020568946A JP7419268B2 JP 7419268 B2 JP7419268 B2 JP 7419268B2 JP 2020568946 A JP2020568946 A JP 2020568946A JP 2020568946 A JP2020568946 A JP 2020568946A JP 7419268 B2 JP7419268 B2 JP 7419268B2
Authority
JP
Japan
Prior art keywords
seq
compound
linker
sequence
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020568946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517471A (ja
JP2021517471A5 (cg-RX-API-DMAC7.html
Inventor
ピーター, シー デムス,
ジュリアン アダムス,
マーティン シュタインバック,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Elicio Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elicio Therapeutics Inc filed Critical Elicio Therapeutics Inc
Publication of JP2021517471A publication Critical patent/JP2021517471A/ja
Publication of JP2021517471A5 publication Critical patent/JP2021517471A5/ja
Priority to JP2024001725A priority Critical patent/JP2024050594A/ja
Application granted granted Critical
Publication of JP7419268B2 publication Critical patent/JP7419268B2/ja
Priority to JP2025283313A priority patent/JP2026067877A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020568946A 2018-03-02 2019-03-01 変異kras配列及び脂質を含む化合物並びにその使用 Active JP7419268B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024001725A JP2024050594A (ja) 2018-03-02 2024-01-10 変異kras配列及び脂質を含む化合物並びにその使用
JP2025283313A JP2026067877A (ja) 2018-03-02 2025-12-26 変異kras配列及び脂質を含む化合物並びにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637879P 2018-03-02 2018-03-02
US62/637,879 2018-03-02
PCT/US2019/020404 WO2019169332A1 (en) 2018-03-02 2019-03-01 Compounds including a mutant kras sequence and a lipid and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001725A Division JP2024050594A (ja) 2018-03-02 2024-01-10 変異kras配列及び脂質を含む化合物並びにその使用

Publications (3)

Publication Number Publication Date
JP2021517471A JP2021517471A (ja) 2021-07-26
JP2021517471A5 JP2021517471A5 (cg-RX-API-DMAC7.html) 2022-03-09
JP7419268B2 true JP7419268B2 (ja) 2024-01-22

Family

ID=67805548

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020568946A Active JP7419268B2 (ja) 2018-03-02 2019-03-01 変異kras配列及び脂質を含む化合物並びにその使用
JP2024001725A Pending JP2024050594A (ja) 2018-03-02 2024-01-10 変異kras配列及び脂質を含む化合物並びにその使用
JP2025283313A Pending JP2026067877A (ja) 2018-03-02 2025-12-26 変異kras配列及び脂質を含む化合物並びにその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024001725A Pending JP2024050594A (ja) 2018-03-02 2024-01-10 変異kras配列及び脂質を含む化合物並びにその使用
JP2025283313A Pending JP2026067877A (ja) 2018-03-02 2025-12-26 変異kras配列及び脂質を含む化合物並びにその使用

Country Status (15)

Country Link
US (4) US12138301B2 (cg-RX-API-DMAC7.html)
EP (1) EP3758713A4 (cg-RX-API-DMAC7.html)
JP (3) JP7419268B2 (cg-RX-API-DMAC7.html)
KR (2) KR102787353B1 (cg-RX-API-DMAC7.html)
CN (2) CN112118847B (cg-RX-API-DMAC7.html)
AU (1) AU2019226586B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017645A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092679A1 (cg-RX-API-DMAC7.html)
IL (1) IL277100B2 (cg-RX-API-DMAC7.html)
MA (1) MA52435A (cg-RX-API-DMAC7.html)
MX (2) MX2020009149A (cg-RX-API-DMAC7.html)
MY (1) MY207748A (cg-RX-API-DMAC7.html)
SA (1) SA520420064B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008433QA (cg-RX-API-DMAC7.html)
WO (1) WO2019169332A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102787353B1 (ko) 2018-03-02 2025-03-26 엘리시오 테라퓨틱스, 인크. 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도
US12247052B2 (en) * 2018-03-02 2025-03-11 Elicio Therapeutics, Inc. CpG amphiphiles and uses thereof
US20240123070A1 (en) * 2021-02-10 2024-04-18 Shanghai GenBase Biotechnology Co., Ltd. Epitope peptide of ras g13d mutant and t cell receptor recognizing ras g13d mutant
KR102818249B1 (ko) 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR102732910B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732913B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732909B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732911B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732912B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500275A (ja) 2003-12-31 2008-01-10 セントカー・インコーポレーテツド N末端の遊離チオールを有する新規な組み換えタンパク質

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0895538B1 (en) 1996-04-19 2002-07-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
JPWO2005001116A1 (ja) 2003-06-17 2006-08-24 明治乳業株式会社 Toll様レセプター強制発現細胞の利用
EP2155889A4 (en) 2007-05-25 2010-06-16 Centocor Ortho Biotech Inc TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
US20120264810A1 (en) 2009-09-22 2012-10-18 The University Of British Columbia Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
AU2012209274A1 (en) * 2011-01-24 2013-09-12 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
JP6283661B2 (ja) * 2012-05-09 2018-02-21 ストライク バイオ インク.Strike Bio,Inc. 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functionalShort−HairpinRNA)
AU2013291125A1 (en) 2012-07-16 2015-01-22 Dicerna Pharmaceuticals, Inc. RNAi pharmaceutical composition capable of suppressing expression of KRAS gene
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
KR102100289B1 (ko) 2013-10-24 2020-04-13 주식회사 다이셀 은 나노 입자 함유 분산액의 제조 방법 및 은 나노 입자 함유 분산액
AU2015314763A1 (en) 2014-09-11 2017-04-06 Vedantra Pharmaceuticals, Inc. Multilamellar lipid vesicle compositions and methods of use
US10940201B2 (en) 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
US10619159B2 (en) * 2016-01-19 2020-04-14 The University Of North Carolina At Chapel Hill Methods and compositions using RNA interference for inhibition of KRAS
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
EP3585428A1 (en) 2017-02-23 2020-01-01 Alpha-o Peptides AG Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
TW201919712A (zh) * 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 運送子(cargomers)
KR102787353B1 (ko) 2018-03-02 2025-03-26 엘리시오 테라퓨틱스, 인크. 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도
US12247052B2 (en) 2018-03-02 2025-03-11 Elicio Therapeutics, Inc. CpG amphiphiles and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500275A (ja) 2003-12-31 2008-01-10 セントカー・インコーポレーテツド N末端の遊離チオールを有する新規な組み換えタンパク質

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chunson Yu et al.,Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.,Mol. Pharmaceutics.,2017年08月07日,Vol.14, No.8,p.2815-2823,doi: 10.1021/acs.molpharmaceut.7b00335
Hua Li Wang et al.,In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer.,Arch. Gynecol. Obstet.,2013年08月03日,Vol.289, No.1,p.155-162,doi: 10.1007/s00404-013-2938-1
Jing Pan et al.,Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine.,Oncotarget,2017年08月01日,Vol.8, No.47,p.82689-82699,doi: 10.18632/oncotarget.19831

Also Published As

Publication number Publication date
JP2021517471A (ja) 2021-07-26
NZ768282A (en) 2024-10-25
AU2019226586A1 (en) 2020-10-15
SA520420064B1 (ar) 2024-04-28
MA52435A (fr) 2021-01-06
KR102787353B1 (ko) 2025-03-26
CN112118847B (zh) 2024-05-28
KR20200141994A (ko) 2020-12-21
EP3758713A4 (en) 2021-12-29
IL277100B1 (en) 2025-02-01
US20260077049A1 (en) 2026-03-19
EP3758713A1 (en) 2021-01-06
IL277100A (en) 2020-10-29
MY207748A (en) 2025-03-16
BR112020017645A2 (pt) 2020-12-29
RU2020132290A (ru) 2022-04-05
US20210060149A1 (en) 2021-03-04
US20250249107A1 (en) 2025-08-07
MX2020009149A (es) 2021-01-15
US20250009888A1 (en) 2025-01-09
CN118421594A (zh) 2024-08-02
JP2026067877A (ja) 2026-04-21
KR20250047830A (ko) 2025-04-04
SG11202008433QA (en) 2020-09-29
WO2019169332A1 (en) 2019-09-06
IL277100B2 (en) 2025-06-01
AU2019226586B2 (en) 2024-08-29
CN112118847A (zh) 2020-12-22
US12138301B2 (en) 2024-11-12
CA3092679A1 (en) 2019-09-06
MX2025011341A (es) 2025-11-03
JP2024050594A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
JP2024050594A (ja) 変異kras配列及び脂質を含む化合物並びにその使用
Jeon et al. Toll-like receptor agonists as cancer vaccine adjuvants
US20250171507A1 (en) Cpg amphiphiles and uses thereof
TWI861015B (zh) 包含抗原肽-佐劑核苷酸結合物之免疫誘導劑及包含其之醫藥組成物
JP2021517471A5 (cg-RX-API-DMAC7.html)
RU2809161C2 (ru) Соединения, включающие мутантную последовательность kras и липид, и их применения
HK40043265A (en) Compounds including a mutant kras sequence and a lipid and uses thereof
HK40043265B (en) Compounds including a mutant kras sequence and a lipid and uses thereof
HK40043266A (en) Cpg amphiphiles and uses thereof
HK40045177B (en) Cpg amphiphiles and uses thereof
HK40045177A (en) Cpg amphiphiles and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240110

R150 Certificate of patent or registration of utility model

Ref document number: 7419268

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150